



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brus et al.

Serial No.: 10/698,086

Filed: October 30, 2003

For: METHODS FOR THE
IDENTIFICATION OF ANTIVIRAL
COMPOUNDS

Confirmation No.: 9184

Examiner: Z. Lucas

Group Art Unit: 1648

Attorney Docket No.: 2578-6158US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL995989785US

Date of Deposit with USPS: October 24, 2005

Person making Deposit: Timothy Palfreyman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

10/26/2005 HDESTA1 00000002 10698086

01 FC:1806

180.00 OP

Other Documents


GALLIMORE et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, Vol. 6.

LEWIN, BENJAMIN, Genes V, 1994, p. 1184, Oxford University Press and Cell Press.

This Supplemental Information Disclosure Statement is filed after the mailing date of the final Office Action under 37 C.F.R. § 1.113, but before payment of the issue fee.

I hereby certify that no item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the statement. Pursuant to 37 C.F.R. § 1.97(d)(ii), applicant hereby requests consideration of the accompanying Supplemental Information Disclosure Statement. The fee pursuant to 37 C.F.R. § 1.17(p) for consideration of this Supplemental Information Disclosure Statement is enclosed.

Respectfully submitted,



Daniel J. Morath, Ph.D.
Registration No. 55,896
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 24, 2005
DJM/bv

Enclosures: Form PTO/SB/08
Copy of documents cited
Check in the amount of \$180.00

Document in ProLaw



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 10/698,086

Filing Date October 30, 2003

First Named Inventor Brus et al.

Group Art Unit 1648

Examiner Name Z. Lucas

Attorney Docket Number 2578-61581JS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GALLIMORE et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, Vol. 6.	
		LEWIN, BENJAMIN, Genes V, 1994, p. 1184, Oxford University Press and Cell Press.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.